ZNF804A: connecting a confirmed schizophrenia risk gene to neuronal, network and behavioural function
Lead Research Organisation:
Cardiff University
Department Name: School of Medicine
Abstract
Millions of motorists set out every morning and the majority of them manage to reach their destinations without incident. But with such a complex and busy network of roads, it does not take much for rush hour to go wrong: just one breakdown can mean gridlock, particularly if the system is already made vulnerable by roadworks. Brains are similar: normally they work well when left to their own devices, but complex diseases like schizophrenia (which afflicts around 1 in 100 people) emerge from very subtle causes, particularly in patients already made vulnerable, by drug abuse for example. Unfortunately, effective treatment of schizophrenia is still hampered by the fact that we do not know exactly what these complex causes are.
We do know that the most important vulnerability factor is family history. If you inherit a faulty secondhand car ? even if it works at first ? it may be you that breaks down and causes rush hour chaos. And if someone in your family has schizophrenia, genes you inherit from them increase your risk of developing the disease. Identifying these genetic faults is therefore critical, since it allows us to identify people at risk, to understand disease mechanism by studying the mechanics of what particular genes contribute to brain function, and hopefully to develop better treatments.
Our recent work surveying around 60,000 people, their genes and their diseases has identified variations in one particular gene consistently linked to schizophrenia. But for this information to be useful, we need to understand what the gene does and why particular versions of it put people at risk of developing debilitating psychotic, depressive and learning problems. To do this, we have engineered mice that also carry variations in the mouse equivalent of the schizophrenia-linked gene. This project will study brain structure, behaviour and brain activity of these mice to see if they share any features in common with schizophrenia patients (e.g. changes in anxiety, learning and memory, sleep). Although schizophrenia cannot be modeled fully in mice, showing that subtle variations of this gene cause symptoms reminiscent of the disease in animal models will provide direct evidence that it is the culprit. These models can then be used to develop and test better therapies that keep brain traffic flowing smoothly.
We do know that the most important vulnerability factor is family history. If you inherit a faulty secondhand car ? even if it works at first ? it may be you that breaks down and causes rush hour chaos. And if someone in your family has schizophrenia, genes you inherit from them increase your risk of developing the disease. Identifying these genetic faults is therefore critical, since it allows us to identify people at risk, to understand disease mechanism by studying the mechanics of what particular genes contribute to brain function, and hopefully to develop better treatments.
Our recent work surveying around 60,000 people, their genes and their diseases has identified variations in one particular gene consistently linked to schizophrenia. But for this information to be useful, we need to understand what the gene does and why particular versions of it put people at risk of developing debilitating psychotic, depressive and learning problems. To do this, we have engineered mice that also carry variations in the mouse equivalent of the schizophrenia-linked gene. This project will study brain structure, behaviour and brain activity of these mice to see if they share any features in common with schizophrenia patients (e.g. changes in anxiety, learning and memory, sleep). Although schizophrenia cannot be modeled fully in mice, showing that subtle variations of this gene cause symptoms reminiscent of the disease in animal models will provide direct evidence that it is the culprit. These models can then be used to develop and test better therapies that keep brain traffic flowing smoothly.
Technical Summary
The recent confirmation of ZNF804A as a susceptibility gene for schizophrenia opens a rare entry point for studying the mechanistic basis of the pathogenesis of this disorder. However, at present, almost nothing is known about the in vivo functions of the encoded protein ZNF804A, or how it contributes to risk for psychopathology. To enable such studies, we have created a number of Zfp804a (the closely related murine orthologue) mutant mouse lines. Here we propose to exploit our development of these lines to allow, for the first time in the intact animal, a comprehensive and integrated characterisation of the functions of a common risk factor for schizophrenia at neurobiological and behavioural levels.
Our preliminary work has established that both ZNF804A and Zfp804a are discretely expressed in brain, particularly in striatal-limbic-cortical circuits associated with cognitive function and neuropsychiatric dysfunction. Consistent with this, our initial functional work has indicated altered behaviour in the Zfp804a mutants; hyperactivity and learning deficits. Capitalizing on expertise and resources in Cardiff and Bristol, we propose to examine relevant aspects of brain structure, behaviour and coordinated neuronal activity in the Zfp804a mutant mouse lines. Specifically, we will combine histological, immunohistochemical, behavioural and in vivo electrophysiological methods to establish whether dysfunction leads to altered brain structure, interneuronal properties, cognitive and emotion-related behaviours, sleep or coordinated limbic-cortical interactions.
Our rapid development and validation of the mutant lines provides a timely and powerful opportunity to define ZNF804A function across multiple scales by combining ongoing cellular work with the systems level analyses proposed herein. Main outcomes will include: (i) unique hypothesis-generating data on functional effects of Zfp804a mutagenesis; (ii) findings from animal work that will integrate with, and inform, ongoing work by the applicants using cellular models and clinical populations and (iii) creation of valid entry points for future work, examining how ZNF804A variants interact with genetic and environmental factors to, ultimately, modify psychiatric disease risk. The work will also establish an optimised experimental framework across the Cardiff and Bristol groups for use in examining other novel risk gene candidates as additional models become available.
Our preliminary work has established that both ZNF804A and Zfp804a are discretely expressed in brain, particularly in striatal-limbic-cortical circuits associated with cognitive function and neuropsychiatric dysfunction. Consistent with this, our initial functional work has indicated altered behaviour in the Zfp804a mutants; hyperactivity and learning deficits. Capitalizing on expertise and resources in Cardiff and Bristol, we propose to examine relevant aspects of brain structure, behaviour and coordinated neuronal activity in the Zfp804a mutant mouse lines. Specifically, we will combine histological, immunohistochemical, behavioural and in vivo electrophysiological methods to establish whether dysfunction leads to altered brain structure, interneuronal properties, cognitive and emotion-related behaviours, sleep or coordinated limbic-cortical interactions.
Our rapid development and validation of the mutant lines provides a timely and powerful opportunity to define ZNF804A function across multiple scales by combining ongoing cellular work with the systems level analyses proposed herein. Main outcomes will include: (i) unique hypothesis-generating data on functional effects of Zfp804a mutagenesis; (ii) findings from animal work that will integrate with, and inform, ongoing work by the applicants using cellular models and clinical populations and (iii) creation of valid entry points for future work, examining how ZNF804A variants interact with genetic and environmental factors to, ultimately, modify psychiatric disease risk. The work will also establish an optimised experimental framework across the Cardiff and Bristol groups for use in examining other novel risk gene candidates as additional models become available.
Publications


Chapman RM
(2019)
Convergent Evidence That ZNF804A Is a Regulator of Pre-messenger RNA Processing and Gene Expression.
in Schizophrenia bulletin

Eddy Jessica B.
(2013)
Effects of ENU mutations of Zfp804a on behavioural phenotypes

Eddy, Jessica
(2012)
Modelling the functions of the confirmed psychosis risk gene ZNF804A
in 8th Federation of European Neuroscience Forum of Neuroscience, Barcelona, July 2012

Eddy, Jessica
(2011)
Modelling the functions of the confirmed psychosis risk gene ZNF804A
in Society for Neuroscience, Washington DC, USA, Nov 2011

Forsyth LH
(2012)
In Vitro and In Vivo Recording of Local Field Potential Oscillations in Mouse Hippocampus.
in Current protocols in mouse biology


Haddon, Josephine
(2013)
Modelling the cognitive function of the confirmed psychosis risk gene ZNF804A
in Society for Neuroscience, San Diego, USA, Nov 2013

Heckenast JR
(2015)
Decoding Advances in Psychiatric Genetics: A Focus on Neural Circuits in Rodent Models.
in Advances in genetics

Humby T
(2011)
Assaying dissociable elements of behavioural inhibition and impulsivity: translational utility of animal models.
in Current opinion in pharmacology
Description | Member of the Lilly Centre for Cognitive Neuroscience |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Member of the P1vital Ltd Advisory Board |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Member of the Wellcome Trust Investigator Awards Funding Committee, Cellular and Molecular Neuroscience Expert Review Group |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Member of the funding committee for ANR (L'Agence Nationale de la Researche) France |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Defining the disturbance in cortical glutamate and GABA function in psychosis, its origins and consequences, Experimental Medicine Challenge |
Amount | £4,252,721 (GBP) |
Funding ID | MR/K020803/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2014 |
End | 02/2018 |
Description | Diverse serotonin 2C-receptor mediated behaviours resulting from snoRNA regulated post-transcriptional modification, |
Amount | £471,803 (GBP) |
Funding ID | BB/J016756/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2012 |
End | 09/2015 |
Description | MRC Centenary Award, Identification of genome-wide targets for neurodevelopment |
Amount | £42,100 (GBP) |
Funding ID | G081418/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2012 |
End | 12/2012 |
Description | MRC Centenary Award, Investigating enduring maternal effects on adult behaviour abnormalities in Zfp804a mutants |
Amount | £18,649 (GBP) |
Funding ID | G081418/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2013 |
End | 07/2013 |
Description | MRC Centre Award |
Amount | £3,200,000 (GBP) |
Funding ID | MR/L010305/1 |
Organisation | Medical Research Council (MRC) |
Department | MRC Centre for Neuropsychiatric Genetics and Genomics |
Sector | Academic/University |
Country | United Kingdom |
Start | 07/2014 |
End | 07/2019 |
Description | WT Strategic Award DEFINE - Defining Endophenotypes from Integrated Neurosciences |
Amount | £5,234,843 (GBP) |
Funding ID | 100202/Z/12/Z |
Organisation | Wellcome Trust |
Department | Wellcome Trust Strategic Award |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2013 |
End | 07/2018 |
Description | Wellcome Trust Seeding Drug Discovery Award Scheme |
Amount | £4,000,000 (GBP) |
Funding ID | G1345 |
Organisation | Wellcome Trust |
Department | Wellcome Trust Translation Award |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2014 |
End | 07/2017 |
Title | Zfp804a ENU point mutant mouse lines |
Description | Creation of two Zfp804a (the mouse orthologue of the psychosis risk gene ZNF804A) ENU point mutation mouse lines from the ENU DNA library held at MRC Harwell. The Exon2 line is a nonsense mutation resulting in a premature stop codon. The Exon4 line is a missense mutation resulting in changes in amino acid sequence. |
Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
Year Produced | 2011 |
Provided To Others? | Yes |
Impact | research with these lines ongoing in Cardiff and Bristol |
Description | MRC Neuromouse: An integrated and translational Research Consortium to study the dysfunction and degeneration of the nervous system. |
Organisation | Medical Research Council (MRC) |
Country | United Kingdom |
Sector | Public |
PI Contribution | Collaboration on generating new genetic models. Disseminating best practice in behavioural analysis. Contributing to consortium meetings. |
Collaborator Contribution | Collaboration on generating new genetic models. Disseminating best practice in genetic and neurobiological analysis. Contributing to consortium meetings. |
Impact | Creation of novel mouse models ongoing. First Neuromouse consortium meeting in Jan 2012 |
Start Year | 2012 |
Description | Using psychiatric genetics and genomic approaches in drug discovery for psychiatric disorders |
Organisation | Takeda Pharmaceutical Company |
Country | Japan |
Sector | Private |
PI Contribution | We are entering into a partnership with the pharmaceutical firm Takeda in order to generate targets and assays with higher predictive validity. We will contribute our knowledge in psychiatric genetics/genomics, our highly phenotyped clinical cohorts, and expertise in cellular and in-vivo models. |
Collaborator Contribution | We are in the final stages of agreeing £4M of funding from Takeda. In addition to the research funding Takeda will contribute particular expertise in target identification and validation. |
Impact | at the beginning of the partnership. |
Start Year | 2018 |
Description | ZNF804A: connecting a confirmed schizophrenia risk gene to neuronal, network and behavioural function |
Organisation | University of Bristol |
Department | School of Physiology, Pharmacology and Neuroscience |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Creation of Zfp804a ENU mutants modelling genetic risk factor for schizophrenia and bipolar disorder. Behavioural analysis of Zfp804a mutants. |
Collaborator Contribution | Structural, neurochemical and neurophysiological analysis of Zfp804a mutants |
Impact | Research programme ongoing |
Start Year | 2011 |
Description | Talk to Swansea 41 Club Oystermouth Yacht Club, Swansea |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | About 30 members of the Swansea 41 Club attended to hear about our work on brain function and in particular the impact of psychiatric genetics on our understanding of brain disorders. Lots of good feedback from the audience. |
Year(s) Of Engagement Activity | 2011 |
Description | Talk to Swansea Ladies Tangent in top room of Italian Restaurant near football ground |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | About 30 members of the Swansea Ladies Tangent attended to hear about our work on brain function and in particular the impact of psychiatric genetics on our understanding of brain disorders. Excellent feedback from the formidable ladies in the audience |
Year(s) Of Engagement Activity | 2012 |